2026-05-22T05:31:27Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/178582024-02-10T20:01:23Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16984

00925njm 22002777a 4500 dc Pascual, Tomás author Martin, Miguel author Fernández-Martínez, Aranzazu author Paré, Laia author Alba, Emilio author Rodríguez-Lescure, Álvaro author Perrone, Giuseppe author Cortés, Javier author Morales, Serafín author Lluch, Ana author Urruticoechea, Ander author González-Farré, Blanca author Galván, Patricia author Jares, Pedro author Rodriguez, Adela author Chic, Nuria author Righi, Daniela author Cejalvo, Juan Miguel author Tonini, Giuseppe author Adamo, Barbara author Vidal, Maria author Villagrasa, Patricia author Muñoz, Montserrat author Prat, Aleix author 2019-04-26 Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities other than gene expression. Methods: PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors. A non-luminal disease score (NOLUS) from 0 to 100, based on percentage of estrogen receptor (ER), progesterone receptor (PR) and Ki67 tumor cells, was derived in a combined cohort of 5 studies (training dataset) and tested in a combined cohort of 3 studies. The performance of NOLUS was estimated using Area Under the ROC Curve (AUC). Results: In the training dataset (n = 903) and compared to luminal disease, non-luminal disease had lower percentage of ER-positive cells (median 65.2 vs. 86.2%, p 10.3389/fonc.2019.00303 2234-943X Frontiers in oncology http://hdl.handle.net/10668/13987 31106144 http://hdl.handle.net/20.500.12105/17858 PAM50 Breast cancer Gene expression Intrinsic subtype Non-luminal A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.